<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

        <ul class="navbar-nav ml-auto">
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
          </ul>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div class="row">
          <div class="col-md-12">
            <h1 class="mb-4">Mitapivat Pipeline Overview <img class="activate" src="images/activate-t.png">
              <span class="badge red-dark float-right">Status: Completed</span>
            </h1>
          </div>
        </div>
        <div class="row">
            <div class="col-md-8">
              <h4 class="font-weight-normal red-text mb-3"><strong>ACTIVATE-T:</strong> A phase 3 trial studying the investigational drug, mitapivat, in patients with PK deficiency who receive <strong>regular drug transfusions<sup>1</sup></strong></h4>
              
              <div class="block">
                <img src="images/mitapivat-pipeline-overview-activate-t.png" />
                <p><strong class="red-text">Primary Efficacy Endpoint:</strong><br/>
                Reduction in transfusion burden during the Optimized Dose Period over a 6 month period compared to the patient’s transfusion history.</p>
              </div>
            </div>
            <div class="col-md-4">
              <div class="block side-block-container">
                <div class="side-block">
                  <p class="mb-1"><strong>Patient Population</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Regularly transfused adults</li>
                      <li>Excludes patients with two non-missense mutations and those homozygous for R479H</li>
                  </ul>
                </div>
                <div class="side-block side-block-gray">
                  <p class="mb-1"><strong>Size</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Up to 40 patients</li>
                  </ul>
                </div>
                <div class="side-block">
                  <p class="mb-1"><strong>Dose</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Dose titration up to optimal transfusion reduction response (5, 20 or 50 mg twice daily)</li>
                  </ul>
                </div>
                <div class="side-block side-block-gray">
                  <p class="mb-1"><strong>Endpoints</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Reduction in transfusion burden</li>
                      <li>Safety</li>
                      <li>Patient-reported outcomes (PRO)</li>
                  </ul>
                </div>
                <div class="side-block">
                  <p class="mb-1"><strong>Control</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>Open-label</li>
                      <li>Reduction of transfusion burden</li>
                  </ul>
                </div>
              </div>
            </div>
        </div>
        <footer>
            <div class="row">
              <div class="col-md-8">
                <p class="text-left mb-4">1≥ 6 transfusion episodes in the past 52 weeks<br/>
                *The safety and efficacy of mitapivat has not been established. There is no guarantee that mitapivat will receive health authority approval or become commercially available in any country for the uses being investigated.</p>
              </div>
              <div class="col-md-4">
                <p class="text-right">For more information (physician/HCP only),<br/>
                please email medinfo@agios.com<br/>
                &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
              </div>
            </div>
        </footer>
      </div>
    </main>


    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
  </body>
</html>